A
Agnes Biggart
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 3
Citations - 354
Agnes Biggart is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: Proteasome inhibitor. The author has an hindex of 3, co-authored 3 publications receiving 266 citations. Previous affiliations of Agnes Biggart include Novartis.
Papers
More filters
Journal ArticleDOI
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness
Shilpi Khare,Advait Nagle,Agnes Biggart,Yin H. Lai,Fang Liang,Lauren C. Davis,S. Whitney Barnes,Casey J. N. Mathison,Elmarie Myburgh,Elmarie Myburgh,Mu-Yun Gao,J. Robert Gillespie,Xianzhong Liu,Jocelyn Tan,Monique Stinson,Ianne C. Rivera,Jaime Ballard,Vince Yeh,Todd Groessl,Glenn C. Federe,Hazel X. Y. Koh,John D. Venable,Badry Bursulaya,Michael Shapiro,Pranab Mishra,Glen Spraggon,Ansgar Brock,Jeremy C. Mottram,Jeremy C. Mottram,Frederick S. Buckner,Srinivasa P. S. Rao,Ben G. Wen,John R. Walker,Tove Tuntland,Valentina Molteni,Richard Glynne,Frantisek Supek +36 more
TL;DR: A selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection, underscores the possibility of developing a single class of drugs for these neglected diseases.
Journal ArticleDOI
Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases
Advait Nagle,Agnes Biggart,Celine Be,Honnappa Srinivas,Andreas Hein,Diana Caridha,Richard J. Sciotti,Brandon S. Pybus,Mara Kreishman-Deitrick,Badry Bursulaya,Yin H. Lai,Mu-Yun Gao,Fang Liang,Casey J. N. Mathison,Xiaodong Liu,Vince Yeh,Smith Jeffrey M,Lerario Isabelle K,Yongping Xie,Chianelli Donatella,Michael Gibney,Ashley Mitchell Berman,Yen Liang Chen,Jan Jiricek,Lauren C. Davis,Xianzhong Liu,Jaime Ballard,Shilpi Khare,Fabian K. Eggimann,Alexandre Luneau,Todd Groessl,Michael Shapiro,Wendy Richmond,Kevin Johnson,Patrick J Rudewicz,Srinivasa P. S. Rao,Christopher Thompson,Tove Tuntland,Glen Spraggon,Richard Glynne,Frantisek Supek,Christian Wiesmann,Valentina Molteni +42 more
TL;DR: LXE408 is described, a structurally related kinetoplastid-selective proteasome inhibitor currently in Phase 1 human clinical trials and presented high-resolution cryo-EM structures of the Leishmania tarentolae proteasomes in complex with LXE408, which provides a compelling explanation for the noncompetitive mode of binding of this novel class of inhibitors of the kinetic proteasom.
Patent
[1,2,4]triazolo[1,5-a]pyrimidine derivatives as protozoan proteasome inhibitors for the treatment of parasitic diseases such as leishmaniasis
Agnes Biggart,Fang Liang,Casey J. N. Mathison,Valentina Molteni,Advait Nagle,Frantisek Supek,Vince Yeh +6 more
TL;DR: In this paper, the authors provided compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein.